132 related articles for article (PubMed ID: 35908879)
1. Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis.
Kang Y; Cui J
Jpn J Infect Dis; 2023 Jan; 76(1):1-6. PubMed ID: 35908879
[TBL] [Abstract][Full Text] [Related]
2. Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR)
Kang Y; Xie L; Yang J; Cui J
Front Cell Infect Microbiol; 2023; 13():1023948. PubMed ID: 37457958
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Ceftazidime/Avibactam Administration in
Dai Y; Chang W; Zhou X; Yu W; Huang C; Chen Y; Ma X; Lu H; Ji R; Ying C; Wang P; Liu Z; Yuan Q; Xiao Y
Drug Des Devel Ther; 2021; 15():2899-2905. PubMed ID: 34262257
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
[TBL] [Abstract][Full Text] [Related]
5. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
6. Superiority of ceftazidime off-label high-dose regimen in PK/PD target attainment during treatment of extensively drug-resistant Pseudomonas aeruginosa infections in cancer patients.
Zavrelova A; Sima M; Malakova J; Rozsivalova P; Paterova P; Zak P; Visek B; Michalickova D; Slanar O; Radocha J
Br J Clin Pharmacol; 2023 Apr; 89(4):1452-1461. PubMed ID: 36422512
[TBL] [Abstract][Full Text] [Related]
7. A model-based analysis of pharmacokinetic-pharmacodynamic (PK/PD) indices of avibactam against Pseudomonas aeruginosa.
Sy SKB; Zhuang L; Xia H; Schuck VJ; Nichols WW; Derendorf H
Clin Microbiol Infect; 2019 Jul; 25(7):904.e9-904.e16. PubMed ID: 30394361
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients.
Stein GE; Smith CL; Scharmen A; Kidd JM; Cooper C; Kuti J; Mitra S; Nicolau DP; Havlichek DH
Surg Infect (Larchmt); 2019 Jan; 20(1):55-61. PubMed ID: 30351195
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
10. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic modelling to evaluate the efficacy of various dosing regimens of ceftazidime/avibactam in patients with pneumonia caused by Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae: a multicentre study in northern China.
Kang Y; Zhou Q; Cui J
J Glob Antimicrob Resist; 2021 Dec; 27():67-71. PubMed ID: 34428596
[TBL] [Abstract][Full Text] [Related]
12. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature.
Meschiari M; Franconi I; Bacca E; Bianco V; Orlando G; Cuomo G; Bedini A; Mussini C
Infection; 2021 Jun; 49(3):549-553. PubMed ID: 33074365
[TBL] [Abstract][Full Text] [Related]
14. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
15. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
16. A descriptive pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime-avibactam for treating DTR gram-negative infections in a case series of critically ill patients undergoing continuous veno-venous haemodiafiltration (CVVHDF).
Gatti M; Rinaldi M; Gaibani P; Siniscalchi A; Tonetti T; Giannella M; Viale P; Pea F
J Crit Care; 2023 Aug; 76():154301. PubMed ID: 37059003
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
19. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
20. Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation.
Song X; Wu Y; Cao L; Yao D; Long M
Front Microbiol; 2019; 10():2777. PubMed ID: 31849910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
